[go: up one dir, main page]

WO2005016934A1 - 3h-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof - Google Patents

3h-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof Download PDF

Info

Publication number
WO2005016934A1
WO2005016934A1 PCT/EP2004/009225 EP2004009225W WO2005016934A1 WO 2005016934 A1 WO2005016934 A1 WO 2005016934A1 EP 2004009225 W EP2004009225 W EP 2004009225W WO 2005016934 A1 WO2005016934 A1 WO 2005016934A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
alkyl
hydrogen
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/009225
Other languages
French (fr)
Inventor
Yves Auberson
Hans-Ulrich Gremlich
Martin Hintersteiner
Willy Kinzy
Rainer Kneuer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Priority to EP04764213A priority Critical patent/EP1658294B1/en
Priority to CA002535873A priority patent/CA2535873A1/en
Priority to BRPI0413703-5A priority patent/BRPI0413703A/en
Priority to MXPA06001891A priority patent/MXPA06001891A/en
Priority to US10/568,841 priority patent/US20070031336A1/en
Priority to JP2006523596A priority patent/JP2007502798A/en
Priority to AU2004264387A priority patent/AU2004264387B2/en
Priority to DE602004004280T priority patent/DE602004004280T2/en
Publication of WO2005016934A1 publication Critical patent/WO2005016934A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Definitions

  • the invention relates to novel near-infrared imaging agents and the use of said agents in a method of labeling amyloid plaques in the brain.
  • agents of the invention are useful in identifying amyloid formation and/or accumulation in neurological and vascular diseases such as Alzheimer's disease.
  • Alzheimer's disease affects 8% of the population over 65, and at least 35% of those above the age of 80.
  • No current method allows a definitive diagnosis of Alzheimer's disease before autopsy and clinicians can only make a diagnostic of probable Alzheimer's disease by comparing the results of several tests and observations leading to a diagnostic accuracy of about 80 to 90%.
  • the identification of an imaging agent with enough specificity and sensitivity for Alzheimer's disease hallmarks would allow major advances in the way Alzheimer's disease is diagnosed.
  • Alzheimer's disease is a neurodegenerative disease of the brain characterized by dementia, cognitive impairment, and memory loss.
  • the beta amyloid peptides A ⁇ 1-40 and A ⁇ 1-42 are major metabolites of the amyloid precursor protein and are found in senile plaques and cerebrovascular amyloid deposits in affected individuals. Formation and accumulation of beta amyloid peptides aggregates in the brain are considered to be critical factors in the development and progression of Alzheimer's disease.
  • Another hallmark of the disease is hyperphosphorylation of the microtubule-associated protein tau with subsequent formation of neurofibrillary tangles.
  • Alzheimer's disease is by postmortem histopathological examination of amyloid deposits and neurofibrillary tangles in the brain. Early appraisal of clinical symptoms for diagnosis is often difficult and unreliable. Therefore, there is a need for in vivo imaging agents, which can specifically demonstrate the location and density of amyloid plaques and neurofibrillary tangles in the living brain. Such agents would be useful diagnostic tools for early detection and monitoring of disease progression, as well as for evaluating the effectiveness of treatments of Alzheimer's disease.
  • Neurofibrillary tangles are cytoskeletal elements composed of aggregates of hyper- phosphorylated tau proteins assembled into periodic restricted amyloid fibers in paired helical filaments.
  • amyloid plaques The major component of amyloid plaques is a 39-43 amino acid long beta- amyloid peptide that is generated from the cleavage of a larger amyloid precursor protein. Except for diffuse plaques formed almost exclusively of beta-amyloid peptides, amyloid plaques are complex lesions containing numerous associated cellular products. Deposits of beta-amyloid occur very early in the disease process long before the clinical symptoms develop.
  • Suitable agents for in vivo brain imaging should be able to cross the blood-brain barrier to enter the brain in sufficient amounts to be detectable by near-infrared radiation, be of low molecular weight and lipophilic. Further, they should have a high affinity and specific binding to amyloid plaques without being rapidly degraded.
  • the present invention provides novel imaging agents that can be used in near-infrared imaging.
  • X and Y represent CH, CH 2 or a divalent or trivalent heteroatom under the proviso that X and Y are not simultaneously CH or CH 2 ; m and o represent independently of each other 0 or 1 , with the proviso that if m is 0 then the dotted line between Y and the neighboring C atom represents a bond and Y is CH or a trivalent heteroatom, if m is 1 then the dotted line between Y and the neighboring C atom is absent and Y is CH 2 or a divalent heteroatom, if o is 0 then the dotted line between X and the neighboring C atom represents a bond and X is CH or a trivalent heteroatom, if o is 1 then the dotted line between X and the neighboring C atom is absent and X is CH 2 or a divalent heteroatom; A represents (CR 3 R ) P and Q represents (CR 9 R 10 ) n ; n and p represent independently of each other 0 or 1 ; R
  • R ⁇ o > R11 and R 12 denote independently of each other hydrogen, (C ⁇ alkyl, carboxy, (C ⁇ alkoxy carbonyl or (C 1 - 4 )alkoxy, or, when X is CH or CH 2 then R 1 and R 2 can also be OH or NR 15 R 16 , or when Y is CH or CH 2 then Ru, R 1 can also be OH or
  • R5, Rs. R 15 and R ⁇ 6 are independently of each other hydrogen, R ⁇ 7 O- C(O)-(C 1 ⁇ t )alkyl or (reactive group)-(C 1 - )alkyl; and R ⁇ 7 represents hydrogen or (Chalky!.
  • compounds of formula I are provided in free base or acid addition salt form wherein X is O, S or CH 2 and Y is O, S or CH 2 , provided that X and Y are not both CH 2 .
  • the compounds of formula bear a cationic charge by virtue of their structure and, hence, are always accompanied by an anion, e.g. an anion resulting from deprotonation of an anorganic or carboxylic acid, such as chloride, bromide, tetrafluoroborate or trifluoroacetate.
  • Hal or halogen denotes I, Br, CI or F.
  • Organic radicals or compounds can be branched or unbranched.
  • alkyl group is branched or unbranched and contains preferably 1 to 4 carbon atoms.
  • Alkyl represents, for example, methyl, ethyl, propyl, butyl.
  • Alkoxy group is branched or unbranched and contains preferably 1 to 4 carbon atoms. Alkoxy represents for example methoxy, ethoxy, propoxy, butoxy.
  • Alkyl carbonyl refers to a radical of the formula -C(O)R a where R a is an alkyl radical as defined above.
  • Fig. 1 The graph shows specific binding of the compound of Example 3 to AD plaques in female 16-months-oId transgenic APP23 mice that are injected i.v. with 3 mg/kg agent of invention. Specific binding is defined as fluorescence signal(transgenic mice) minus fluorescence signal(non-transgenic mice) divided by fluorescence signal(transgenic mice).
  • compounds according to formula I are capable of being detected by near-infrared radiation of wavelength 600-1000 nm.
  • compounds of the invention preferably exhibit the following properties: (i) specificity for amyloid plaques (ii) blood-brain barrier penetration (iii) solubility (iv) capable of being detected by near-infrared radiation
  • Specificity of a compound of the invention for amyloid plaques is determined to have occurred when there is a chemical interaction between a compound of the invention and said amyloid plaque.
  • This chemical association includes: covalent bonds, ionic bonds, hydrophilic-hydrophilic interactions or hydrophobic-hydrophobic interactions.
  • composition comprising a compound of formula I and a pharmaceutically acceptable excipient or diluent.
  • composition comprising a compound of the invention capable of being detected by near-infrared radiation of wavelength 600 - 1000 nm.
  • compositions according to the invention comprise a compound of the invention and are intended to include any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, compatible with application. Except insofar as any conventional media or agent is compatible with the active compound, such media can be used in the compositions of the invention. Supplementary active compounds can also be incorporated into the compositions.
  • composition of the invention when applied to a subject, it is formulated to be compatible with its intended route of application.
  • routes of application include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid or cyclodextrin; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • Compounds or compositions of the invention can be attached to cells or vectors and be delivered to a subject by, for example, intravenous injection, local administration or by stereotactic injection.
  • Composition of the present invention may further include one or more of the following components, at the concentrations noted, with the final osmolality adjusted with sodium chloride or potassium chloride to from about 250 milliosmoles (m Osm) to about 330 milliosmoles: K/NaHCO 3 at a concentration of about 5-50 m ; MgCI 2 at a concentration of about 0-88 m ; KCI at a concentration of about 4-104 mM; Na 3 PO 4 at a concentration of about 0-1.5 mM; and CaCI 2 at a concentration of about 0- 0.6 mM.
  • K/NaHCO 3 at a concentration of about 5-50 m
  • MgCI 2 at a concentration of about 0-88 m
  • KCI at a concentration of about 4-104 mM
  • Na 3 PO 4 at a concentration of about 0-1.5 mM
  • CaCI 2 at a concentration of about 0- 0.6 mM.
  • the buffer solution is formulated to maintain the pH of the autoretic reagent composition at between about 7 to about 8, most preferably about 7.4, and, accordingly, may include one or more of the following components, in the concentration ranges given, with the final osmolality of from about 280 m Osm to about 300 m Osm: Tris TEA at a concentration of about 0-150 mM; K 2 Ox EDTA at a concentration of about 0-121 mM; and KCI/NaCI at a concentration of about 0- 155 mM.
  • Compositions of the present invention may also include certain anions and cations (e.g., alkyl metal chlorides) to facilitate penetration through cell membranes.
  • anions include bicarbonate, chloride borate, barbital, oxalate (Ox), or ethylenediamine- tetraacetic acid (EDTA). It is to be noted that not all anions have been found to be effective in promoting penetration across cell membranes.
  • suitable cations include sodium (e.g., NaCI), potassium (e.g., KCI), trishydroxymethylamino methane (Tris), (Trisfhydroxymethylj-aminomethane-hydrochloric acid (Tris-HCI), or triethanolamine (TEA).
  • conjugates comprising a compound of the invention covalently linked to a biomolecule through a reactive group.
  • Biomolecules may be selected from the group consisting of: nucleoside, nucleotide, oligonucleotide, nucleic acid, protein, peptide, amino acid, polysaccharide, oligosaccharide, monosaccharide, drug or a small molecule, for example, less than MW 500.
  • the term "reactive group” as used herein means in particular a group as defined in Table 1.
  • radicals and symbols A, X, R 1f R 2 , R 5 , Re, R ⁇ 4 and o have the meanings as defined in claim 1 for a compound of formula I, with a nitroso or diazo compound of formula IV
  • Compounds of the invention can be produced, for example, as described in Examples 1-5. Working up the reaction mixtures and purification of the compounds thus obtained may be carried out in accordance to known procedures. Acid addition salts may be produced from the free bases in known manner, and vice-versa.
  • the starting materials of formula III and IV are known or can be prepared according to methods known in the art or those disclosed in the Examples.
  • the invention provides a method of labeling target structures in the brain by applying a compound or composition of the invention.
  • applying is used in its broadest sense and includes any method of introducing the compounds or compositions of the invention to a subject's body or part of the body.
  • a subject refers to any mammal including, for example, a human, rat, mouse, dog, cat or swine.
  • a compound or composition of the invention may be systemically or locally.
  • a compound of the invention may be applied to the subject such that it is delivered throughout the body.
  • a compound of the invention may be applied locally to a specific organ or tissue of interest. This local application may be either in vivo in a living subject or in vitro after a tissue sample has been removed from the body. Examples of the application of a compound or composition of the invention are described in the Examples section.
  • the imaging of amyloid deposits can also be carried out quantitatively so that the amount of amyloid deposits can be determined.
  • the fluorescence images are analyzed on a region of interest basis.
  • a method of labeling target structures in the brain comprising:
  • a method of labeling target structures in the brain comprising:
  • composition comprising a compound of formula I, wherein X is O,S, or C and Y is O, S or CH 2 with the proviso that X and Y are not both CH 2
  • a method of labeling target structures in the brain comprising:
  • X and Y represent CH, CH 2 or a divalent or trivalent heteroatom under the proviso that X and Y are not simultaneously CH or CH 2 ; m and o represent independently of each other 0 or 1 , with the proviso that if m is 0 then the dotted line between Y and the neighboring C atom represents a bond and Y is CH or a trivalent heteroatom, if m is 1 then the dotted line between Y and the neighboring C atom is absent and Y is CH 2 or a divalent heteroatom, if o is 0 then the dotted line between X and the neighboring C atom represents a bond and X is CH or a trivalent heteroatom, if o is 1 then the dotted line between X and the neighboring C atom is absent and X is CH 2 or a divalent heteroatom; A represents (CR 3 R 4 ) P and Q represents (CR 9 R 10 ) n ; n and p represent independently of each other 0 or 1
  • R 1 5 and R ⁇ 6 are independently of each other hydrogen, (Chalky!, R ⁇ 7 O- C(O)-(C 1 ⁇ )alkyl or (reactive group)-(C M )alkyl; and R 17 represents hydrogen or (C ⁇ alkyl; in free base or acid addition salt form, or of formula II
  • Re, R 7 , R 13 , and R 14 denote independently of each other hydrogen, halogen, (C ⁇ . 4 )alkylSO 2 , SO 3 H, carboxy, (C ⁇ )alkoxy carbonyl, (C ⁇ Jalkoxy, OH or NR 15 R 16 , and R 21 and R 22 are phenyl, phenylalkyl, carboxy or halogen; R and R 22 together with the carbon atoms to which they are attached can also form a saturated or unsaturated ring; R 21 and R 13 together with the carbon atoms to which they are attached can also form a saturated or unsaturated ring; R5, Re, R 20 and R 23 are hydrogen, (Chalky!, (C ⁇ alkoxy, polyoxyhydrocarbyl, phenyl, phenylalkyl; R 8 and R 20 together with the nitrogen atom to which they are attached can form a saturated or unsaturated ring, R 23 and R 5 together with the nitrogen atom to which they are attached can form
  • Compounds and compositions of the invention are useful as markers for labeling pathological structures such as amyloid plaques in the brain. This is useful in identifying, diagnosing and preventing diseases involving the formation and/or accumulation of amyloid plaques and for monitoring the effectiveness of therapeutic treatments of diseases involving formation and/or accumulation of amyloid plaques. These diseases include, for example, Alzheimer's disease, Down 's syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis.
  • compounds and compositions of the invention are used as near-infrared imaging agents for identifying amyloid plaques in the brain.
  • the following examples are illustrative, but not limiting, of the method and compositions of the present invention.
  • Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered and obvious to those skilled in the art are within the spirit and scope of the invention.
  • Example 1 Synthesis of 4.8-D-methyl-2,3A9,10.11-hexahvdro-1.6-dioxa-4-13-diaza-8- azonia-pentacen chloride
  • 3 H, 3 J 6.5 Hz, 2'-H), 1.94 (m, 2 H, 10-H), 2.89 (m, 2 H, 11-H), 3.34 (s, 3 H, 3 % -H), 3.67 (m, 2 H, 9-H), 3.73 (m, 2H, V-H), 3.79 (m, 2 H, 3-H), 4.34 (m, 2 H, C-2), 6.99 (s, 1 H, 7-H), 7.01 (s, 1 H, 5-H), 7.22 (s, 1 H, 14-H), 7.55 (s, 1 H, 6-H).
  • UV/VIS and fluorescence spectra are recorded and analyzed.
  • a Lambda 19 spectrometer from Perkin Elmer equipped with cells of 1.000 cm pathlength is used. The scan rate is 120 nm/min.
  • Example 7 Labeling of APP23 mouse and human Alzheimer disease (AD) brain sections using a compound of the invention or Thioflavine S
  • the agent of the invention is dissolved in dimethylsulfoxide and diluted to a final concentration of 0.01 % with 50% Ethanol, Thioflavine S is dissolved in 50% Ethanol, final concentration is 0.01 %.
  • Example 8 In vitro binding properties to amyloid plaques Binding of the agent of the invention (compound Ex.3) to aggregated A ⁇ peptide A ⁇ 1-40 in solution is investigated by differential fluorescence spectroscopy and thioflavine displacement.
  • the fluorescence spectrum of the agent of the invention shows slightly reduced fluorescence intensity in the range of 680-720 nm upon ⁇ -amyioid binding. Difference spectra are recorded at different concentrations of the agent of the invention (compound Ex.3) with the magnitude of the fluorescence shift being dependent on the concentration of aggregated A ⁇ .
  • the experiment is done at thioflavine concentrations from 0.37 ⁇ M - 3 ⁇ M, the apparent binding constants for the agent of the invention (compound Ex.3) are between 0.1 ⁇ M - 0.2 ⁇ M at all thioflavine concentrations and do not increase at higher thioflavine concentrations.
  • Injection solution is prepared fresh by dissolving 10 mg of the agent of invention in 0.2 mL dimethylsulfoxide diluted with 9.8 ml sterile water. Lower concentrations are prepared by further dilution with water.
  • Four APP23 female mice at 21 month of age receive one single injection of the compound (Injection volume: 1 ml/100gr body weight). The treated animals are killed by decapitation after one hour. The brains are removed and frozen on dry ice. 14 ⁇ m thick sections are cut in a cryotome, thaw mounted and air-dried. Staining is performed as described above. Sections are analyzed using conventional fluorescence microscopy and confocal microscopy.
  • Example 10 Label and real-time detection of beta amyloid plagues and neurofibrillary tangles in vivo using near-infrared imaging

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention provides compounds of formula (I) wherein X and Y represent CH, CH2 or a divalent or trivalent heteroatom under the proviso that X and Y are not simultaneously CH or CH2; m and o represent independently of each other 0 or 1, with the proviso that if m is 0 then the dotted line between Y and the neighboring C atom represents a bond and Y is CH or a trivalent heteroatom, if m is 1 then the dotted line between Y and the neighboring C atom is absent and Y is CH2 or a divalent heteroatom, if o is 0 then the dotted line between X and the neighboring C atom represents a bond and X is CH or a trivalent heteroatom, if o is 1 then the dotted line between X and the neighboring C atom is absent and X is CH2 or a divalent heteroatom; A represents (CH3CR4)p and Q represents (CR9R10)n; n and p represent independently of each other 0 or 1; R6, R7, R13 and R14 denote independently of each other hydrogen, halogen, (C1-4)alkyl, (C1-4)alkylSO2, SO3H, carboxy, (C1-4)alkoxy carbonyl, (C1-4)alkoxy, OH or NR15R16; R1, R2, R3, R4, R9, R10, R11 and R12 denote independently of each other hydrogen, (C1-4)alkyl, carboxy, (C1-4)alkoxy carbonyl or (C1-4)alkoxy, or, when X is CH or CH2 then R1 and R2 can also be OH or NR15R16, or when Y is CH or CH2 then R11, R12 can also be OH or NR15R16; R5, R8, R15 and R16 are independently of each other hydrogen, (C1-4)alkyl, (C1-4)alkoxy, R17O-C(O)-(C1-4)alkyl or (reactive group)-(C1-4)alkyl; and R17 represents hydrogen or (C1-4)alkyl; compositions comprising such compounds, a process for the production of such compounds of formula (I), a method of labeling target structures, especially amyloid plaques, in the brain, a method for identifying Alzheimer's disease, use of a compound of formula I as a near-infrared imaging agent and a conjugate comprising a compound of formula (I) covalently linked to a biomolecule through a reactive group.

Description

3H-Phenoxazine Derivatives suitable as Near-Infrared Imaging Agents. Preparation and Use thereof
Summary of the Invention
The invention relates to novel near-infrared imaging agents and the use of said agents in a method of labeling amyloid plaques in the brain. In particular, agents of the invention are useful in identifying amyloid formation and/or accumulation in neurological and vascular diseases such as Alzheimer's disease.
Background of the Invention
Alzheimer's disease affects 8% of the population over 65, and at least 35% of those above the age of 80. No current method allows a definitive diagnosis of Alzheimer's disease before autopsy and clinicians can only make a diagnostic of probable Alzheimer's disease by comparing the results of several tests and observations leading to a diagnostic accuracy of about 80 to 90%. The identification of an imaging agent with enough specificity and sensitivity for Alzheimer's disease hallmarks would allow major advances in the way Alzheimer's disease is diagnosed.
Alzheimer's disease is a neurodegenerative disease of the brain characterized by dementia, cognitive impairment, and memory loss. The beta amyloid peptides Aβ1-40 and Aβ1-42 are major metabolites of the amyloid precursor protein and are found in senile plaques and cerebrovascular amyloid deposits in affected individuals. Formation and accumulation of beta amyloid peptides aggregates in the brain are considered to be critical factors in the development and progression of Alzheimer's disease. Another hallmark of the disease is hyperphosphorylation of the microtubule-associated protein tau with subsequent formation of neurofibrillary tangles.
Currently, the only definitive confirmation of Alzheimer's disease is by postmortem histopathological examination of amyloid deposits and neurofibrillary tangles in the brain. Early appraisal of clinical symptoms for diagnosis is often difficult and unreliable. Therefore, there is a need for in vivo imaging agents, which can specifically demonstrate the location and density of amyloid plaques and neurofibrillary tangles in the living brain. Such agents would be useful diagnostic tools for early detection and monitoring of disease progression, as well as for evaluating the effectiveness of treatments of Alzheimer's disease. Neurofibrillary tangles are cytoskeletal elements composed of aggregates of hyper- phosphorylated tau proteins assembled into periodic restricted amyloid fibers in paired helical filaments. The major component of amyloid plaques is a 39-43 amino acid long beta- amyloid peptide that is generated from the cleavage of a larger amyloid precursor protein. Except for diffuse plaques formed almost exclusively of beta-amyloid peptides, amyloid plaques are complex lesions containing numerous associated cellular products. Deposits of beta-amyloid occur very early in the disease process long before the clinical symptoms develop.
The direct imaging of amyloid deposits in vivo is difficult as the deposits have many of the same physical properties (e.g. density and water content) as normal tissues. However, processes for irradiation and imaging of biological tissues with light of the wavelength range from 600 to 1000 nm in the near-infrared (NIR) region are available.
In fluorescence imaging, the energy from an external source of light, e.g. a laser is absorbed and almost immediately re-emitted at a longer wavelength of lower energy. Since biological tissue has a relatively high permeability for long-wave light of the 600 to 1000 nm spectral region, both the detection of non-absorbed radiation in the form of a transmission visualization and the re-emitted fluorescence radiation can provide tissue-specific data. Imaging of deeper tissues (that is, in the range of centimeters) is accomplished by using NIR light in combination with NIR fluorochromes. Near-infrared fluorescence imaging has the advantage of minimizing tissue autofluorescence thus improving target/background ratios.
Suitable agents for in vivo brain imaging should be able to cross the blood-brain barrier to enter the brain in sufficient amounts to be detectable by near-infrared radiation, be of low molecular weight and lipophilic. Further, they should have a high affinity and specific binding to amyloid plaques without being rapidly degraded.
Description of the Invention
The present invention provides novel imaging agents that can be used in near-infrared imaging.
In one aspect of the invention, compounds of formula I
Figure imgf000005_0001
are provided in free base or acid addition salt form, wherein
X and Y represent CH, CH2 or a divalent or trivalent heteroatom under the proviso that X and Y are not simultaneously CH or CH2; m and o represent independently of each other 0 or 1 , with the proviso that if m is 0 then the dotted line between Y and the neighboring C atom represents a bond and Y is CH or a trivalent heteroatom, if m is 1 then the dotted line between Y and the neighboring C atom is absent and Y is CH2 or a divalent heteroatom, if o is 0 then the dotted line between X and the neighboring C atom represents a bond and X is CH or a trivalent heteroatom, if o is 1 then the dotted line between X and the neighboring C atom is absent and X is CH2 or a divalent heteroatom; A represents (CR3R )P and Q represents (CR9R10)n; n and p represent independently of each other 0 or 1 ; R6, R7, R13, and Rι4 denote independently of each other hydrogen, halogen, (d-^alkyl, (C-i. 4)alkylSO2, SO3H, carboxy, (C^)alkoxy carbonyl, (C^alkoxy, OH or NR15R16; R-i. R2. R3. R4. 9. Rιo> R11 and R12 denote independently of each other hydrogen, (C^alkyl, carboxy, (C^alkoxy carbonyl or (C1-4)alkoxy, or, when X is CH or CH2 then R1 and R2 can also be OH or NR15R16, or when Y is CH or CH2 then Ru, R1 can also be OH or
R5, Rs. R15 and Rι6 are independently of each other hydrogen,
Figure imgf000005_0002
Rι7O- C(O)-(C1^t)alkyl or (reactive group)-(C1- )alkyl; and Rι7 represents hydrogen or (Chalky!.
In a preferred aspect of the invention, compounds of formula I are provided in free base or acid addition salt form wherein X is O, S or CH2 and Y is O, S or CH2, provided that X and Y are not both CH2. The compounds of formula bear a cationic charge by virtue of their structure and, hence, are always accompanied by an anion, e.g. an anion resulting from deprotonation of an anorganic or carboxylic acid, such as chloride, bromide, tetrafluoroborate or trifluoroacetate.
Above and elsewhere in the present description the following terms have the following meanings:
Hal or halogen denotes I, Br, CI or F.
Organic radicals or compounds can be branched or unbranched.
An "alkyl group" is branched or unbranched and contains preferably 1 to 4 carbon atoms. Alkyl represents, for example, methyl, ethyl, propyl, butyl.
An "alkoxy group" is branched or unbranched and contains preferably 1 to 4 carbon atoms. Alkoxy represents for example methoxy, ethoxy, propoxy, butoxy.
"Alkyl carbonyl" refers to a radical of the formula -C(O)Ra where Ra is an alkyl radical as defined above.
Short Description of the Figure
Fig. 1 : The graph shows specific binding of the compound of Example 3 to AD plaques in female 16-months-oId transgenic APP23 mice that are injected i.v. with 3 mg/kg agent of invention. Specific binding is defined as fluorescence signal(transgenic mice) minus fluorescence signal(non-transgenic mice) divided by fluorescence signal(transgenic mice).
In one aspect of the invention, compounds according to formula I are capable of being detected by near-infrared radiation of wavelength 600-1000 nm.
In yet another aspect of the invention, compounds of the invention preferably exhibit the following properties: (i) specificity for amyloid plaques (ii) blood-brain barrier penetration (iii) solubility (iv) capable of being detected by near-infrared radiation
Specificity of a compound of the invention for amyloid plaques is determined to have occurred when there is a chemical interaction between a compound of the invention and said amyloid plaque. This chemical association includes: covalent bonds, ionic bonds, hydrophilic-hydrophilic interactions or hydrophobic-hydrophobic interactions.
In one aspect of the invention, a composition is provided comprising a compound of formula I and a pharmaceutically acceptable excipient or diluent.
In yet another aspect of the invention, a composition is provided comprising a compound of the invention capable of being detected by near-infrared radiation of wavelength 600 - 1000 nm.
Compositions according to the invention comprise a compound of the invention and are intended to include any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, compatible with application. Except insofar as any conventional media or agent is compatible with the active compound, such media can be used in the compositions of the invention. Supplementary active compounds can also be incorporated into the compositions.
For example, when a composition of the invention is applied to a subject, it is formulated to be compatible with its intended route of application. Examples of routes of application include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid or cyclodextrin; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
Compounds or compositions of the invention can be attached to cells or vectors and be delivered to a subject by, for example, intravenous injection, local administration or by stereotactic injection.
Composition of the present invention may further include one or more of the following components, at the concentrations noted, with the final osmolality adjusted with sodium chloride or potassium chloride to from about 250 milliosmoles (m Osm) to about 330 milliosmoles: K/NaHCO 3 at a concentration of about 5-50 m ; MgCI 2 at a concentration of about 0-88 m ; KCI at a concentration of about 4-104 mM; Na 3 PO 4 at a concentration of about 0-1.5 mM; and CaCI 2 at a concentration of about 0- 0.6 mM. Preferably, the buffer solution is formulated to maintain the pH of the autoretic reagent composition at between about 7 to about 8, most preferably about 7.4, and, accordingly, may include one or more of the following components, in the concentration ranges given, with the final osmolality of from about 280 m Osm to about 300 m Osm: Tris TEA at a concentration of about 0-150 mM; K 2 Ox EDTA at a concentration of about 0-121 mM; and KCI/NaCI at a concentration of about 0- 155 mM.
Compositions of the present invention may also include certain anions and cations (e.g., alkyl metal chlorides) to facilitate penetration through cell membranes. Non-limiting examples of anions include bicarbonate, chloride borate, barbital, oxalate (Ox), or ethylenediamine- tetraacetic acid (EDTA). It is to be noted that not all anions have been found to be effective in promoting penetration across cell membranes. Nonlimiting examples of suitable cations include sodium (e.g., NaCI), potassium (e.g., KCI), trishydroxymethylamino methane (Tris), (Trisfhydroxymethylj-aminomethane-hydrochloric acid (Tris-HCI), or triethanolamine (TEA).
In a further aspect of the invention, conjugates are provided comprising a compound of the invention covalently linked to a biomolecule through a reactive group. Biomolecules may be selected from the group consisting of: nucleoside, nucleotide, oligonucleotide, nucleic acid, protein, peptide, amino acid, polysaccharide, oligosaccharide, monosaccharide, drug or a small molecule, for example, less than MW 500. The term "reactive group" as used herein means in particular a group as defined in Table 1.
Figure imgf000009_0002
In another aspect of the invention, a process for the production of compounds of formula I and their salts is provided, comprising the steps of reacting a phenol derivative of formula III
Figure imgf000009_0001
wherein the radicals and symbols A, X, R1f R2, R5, Re, Rι4 and o have the meanings as defined in claim 1 for a compound of formula I, with a nitroso or diazo compound of formula IV
Figure imgf000010_0001
wherein the radicals and symbols Q, Y, R7, R8, Ru, R12, R13 and m have the meanings as defined in claim 1 for a compound of formula I, R18 represents oxo or p-nitrophenyl-N= and 19 represents hydroxy; and recovering the resulting compound of formula I in free base form or in form of an acid addition salt.
Compounds of the invention can be produced, for example, as described in Examples 1-5. Working up the reaction mixtures and purification of the compounds thus obtained may be carried out in accordance to known procedures. Acid addition salts may be produced from the free bases in known manner, and vice-versa. The starting materials of formula III and IV are known or can be prepared according to methods known in the art or those disclosed in the Examples.
The invention provides a method of labeling target structures in the brain by applying a compound or composition of the invention. The term "applying" is used in its broadest sense and includes any method of introducing the compounds or compositions of the invention to a subject's body or part of the body. A subject refers to any mammal including, for example, a human, rat, mouse, dog, cat or swine.
The application of a compound or composition of the invention to a subject may be systemically or locally. For example, a compound of the invention may be applied to the subject such that it is delivered throughout the body. Alternatively, a compound of the invention may be applied locally to a specific organ or tissue of interest. This local application may be either in vivo in a living subject or in vitro after a tissue sample has been removed from the body. Examples of the application of a compound or composition of the invention are described in the Examples section.
After a compound or composition of the invention is applied, detection of the compound using near-infrared radiation occurs. The amount of compound needed to be detected can readily be determined by those skilled in the art. Increasing the amount of compound of the invention and comparison to a suitable control can determine the precise dosage of compound needed.
The imaging of amyloid deposits can also be carried out quantitatively so that the amount of amyloid deposits can be determined. For quantitative analysis, the fluorescence images are analyzed on a region of interest basis.
In an aspect of the invention, a method of labeling target structures in the brain is provided, comprising:
(i) applying a composition comprising a compound of formula I in free base or acid addition salt form
(ii) allowing sufficient time for said compound to be chemically associated with the target structure in the brain
(iii) detecting said compound using near-infrared radiation.
In another aspect of the invention, a method of labeling target structures in the brain is provided comprising:
(i) applying a composition comprising a compound of formula I, wherein X is O,S, or C and Y is O, S or CH2 with the proviso that X and Y are not both CH2
(ii) allowing sufficient time for said compound to be chemically associated with the target structure in the brain and
(iii) detecting said compound using near-infrared radiation.
In yet another aspect of the invention, a method of labeling target structures in the brain is provided comprising:
(i) applying a composition comprising a compound of formula I
Figure imgf000011_0001
wherein X and Y represent CH, CH2 or a divalent or trivalent heteroatom under the proviso that X and Y are not simultaneously CH or CH2; m and o represent independently of each other 0 or 1 , with the proviso that if m is 0 then the dotted line between Y and the neighboring C atom represents a bond and Y is CH or a trivalent heteroatom, if m is 1 then the dotted line between Y and the neighboring C atom is absent and Y is CH2 or a divalent heteroatom, if o is 0 then the dotted line between X and the neighboring C atom represents a bond and X is CH or a trivalent heteroatom, if o is 1 then the dotted line between X and the neighboring C atom is absent and X is CH2 or a divalent heteroatom; A represents (CR3R4)P and Q represents (CR9R10)n; n and p represent independently of each other 0 or 1 ; R6, R7, R13, and R14 denote independently of each other hydrogen, halogen, (C^Jalkyl, (Ci- 4)alkylSO2, SO3H, carboxy,
Figure imgf000012_0001
OH or NR15R16; Rι, R2, R3, R4, R9, R10, R11 and R12 denote independently of each other hydrogen, (C^alkyl, carboxy,
Figure imgf000012_0002
or, when X is CH or CH2 then Rt and R2 can also be OH or NR15R16, or when Y is CH or CH2 then Ru, R12 can also be OH or
Rs, Rs, R15 and Rή6 are independently of each other hydrogen, (Chalky!,
Figure imgf000012_0003
Rι7O- C(O)-(C1^)alkyl or (reactive group)-(CM)alkyl; and R17 represents hydrogen or (C^alkyl; in free base or acid addition salt form, or of formula II
Figure imgf000012_0004
wherein
Re, R7, R13, and R14 denote independently of each other hydrogen, halogen,
Figure imgf000012_0005
(Cι. 4)alkylSO2, SO3H, carboxy, (C^)alkoxy carbonyl, (C^Jalkoxy, OH or NR15R16, and R21 and R22 are
Figure imgf000012_0006
phenyl, phenylalkyl, carboxy or halogen; R and R22 together with the carbon atoms to which they are attached can also form a saturated or unsaturated ring; R21 and R13 together with the carbon atoms to which they are attached can also form a saturated or unsaturated ring; R5, Re, R20 and R23 are hydrogen, (Chalky!, (C^alkoxy, polyoxyhydrocarbyl, phenyl, phenylalkyl; R8 and R20 together with the nitrogen atom to which they are attached can form a saturated or unsaturated ring, R23 and R5 together with the nitrogen atom to which they are attached can form a saturated or unsaturated ring, R22 and R23 together with the atoms to which they are attached can form a saturated or unsaturated ring, R5 together with R6 together with the atoms to which they are attached can form a saturated or unsaturated ring, R7 together with R8 together with the atoms to which they are attached can form a saturated or unsaturated ring, R20 together with R21 together with the atoms to which they are attached can form a saturated or unsaturated ring, (ii) allowing sufficient time for said compound to be chemically associated with the target structure in the brain, and (iii) detecting said compound using near-infrared radiation.
Compounds and compositions of the invention are useful as markers for labeling pathological structures such as amyloid plaques in the brain. This is useful in identifying, diagnosing and preventing diseases involving the formation and/or accumulation of amyloid plaques and for monitoring the effectiveness of therapeutic treatments of diseases involving formation and/or accumulation of amyloid plaques. These diseases include, for example, Alzheimer's disease, Down 's syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis.
In another aspect of the invention, compounds and compositions of the invention are used as near-infrared imaging agents for identifying amyloid plaques in the brain. The following examples are illustrative, but not limiting, of the method and compositions of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered and obvious to those skilled in the art are within the spirit and scope of the invention.
Example 1: Synthesis of 4.8-D-methyl-2,3A9,10.11-hexahvdro-1.6-dioxa-4-13-diaza-8- azonia-pentacen chloride
A solution of 1-methyl-1,2,3,4-tetrahydro-quinolin-7-ol (20.0 mg, 123 μmol) in water (500 μl) and 2 M HCI (100 μl) is cooled to 0°C and an aqueous solution of sodium nitrite (8.57 mg, 123 μmol) is added. The reaction mixture is stirred at 0CC for 60 min, neutralized with a saturated solution of NaHCO3and extracted with ethyl acetate. The organic phase is dried with MgSO and the solvent is removed under reduced pressure. The obtained nitroso intermediate and 4-methyl-2-H-benz[1,4]oxazin-6-ol (24.5 mg, 148 μmol) are dissolved in a mixture of ethanol (1.00 ml) and 2 M HCI (100 μl) and heated under reflux for 1 h. The solution is concentrated under reduced pressure and the residue is purified by column chromatography (SiO2, dichloromethane/methanol = 10/3) providing the title compounds as blue crystals, mp: 245-248 °C; 1H NMR (500 MHz): δ = 2.05 (tt, 2 H, = 6.1 Hz, = 5.5 Hz, 10-H), 2.92 (t, 2 H, 3J = 6.1 Hz, 11-H), 3.31 (s, 3 H, 1*-H), 3.33 (s, 3 H, 2 -H), 3.70 (t, 2 H, 3J = 5.5 Hz, 9-H), 3.78 (t, 2-H, 3J = 4.9 Hz, 3-H), 4.35 (t, 2 H, 3J = 4.9 Hz, 2-H), 6.82 (s, 1 H, 7- H), 6.90 (s, 1 H, 5-H), 7.09 (s, 1 H, 11-H), 7.40 (s, 1 H, 12-H).
Example 2: Synthesis of 8-Ethyl-4-methyl-2.3,4.9.10.11-hexahvdro-1.6-dioxa-4.13-diaza-8- azonia-pentacen chloride
A solution of 1-ethyl-1,2.3,4-tetrahydro-quinolin-7-ol (50.0 mg, 276 μmol) in water (1 ml) and 2 M HCI (250 μl) is cooled to 0°C and a solution of sodium nitrite (20.0 mg, 287 μmol) in water (400 μl) is added. The reaction mixture is stirred at 0°C for 60 min, neutralized with a saturated solution of NaHCO3 and extracted with ethyl acetate. The organic phase is dried with MgSO4 and the solvent is removed under reduced pressure. The nitroso intermediate (25.0 mg, 121 μmol) and 4-methyl-2-H-benz[1 ,4]oxazin-6-ol (20.1 mg, 121 μmol) are dissolved in a mixture of ethanol (750 μl) and 2 M HCI (124 μl) and heated under reflux for 3 h. The solution is concentrated under reduced pressure and the residue is purified by column chromatography (SiO2, dichloromethane/methanol/water/ acetic acid = 10/10/1/1) to furnish the title compound as blue crystals, mp: 245-247 °C; 1H NMR (500 MHz): δ = 1.24 (t,
3 H, 3J = 6.5 Hz, 2'-H), 1.94 (m, 2 H, 10-H), 2.89 (m, 2 H, 11-H), 3.34 (s, 3 H, 3%-H), 3.67 (m, 2 H, 9-H), 3.73 (m, 2H, V-H), 3.79 (m, 2 H, 3-H), 4.34 (m, 2 H, C-2), 6.99 (s, 1 H, 7-H), 7.01 (s, 1 H, 5-H), 7.22 (s, 1 H, 14-H), 7.55 (s, 1 H, 6-H).
Example 3: 4,8-Dimethyl-3,8,9, 10-tetrahydro-2H-1.6.11 -trioxa-8.13-diaza-4-azonia-pentacen tetrafluoroborate
4-Nitro-benzenediazonium tetrafluoroborate (574 mg, 2.42 mmol) is dissolved in 10% H2SO4 (400 μl) and is added to a solution of 4-methyl-2-H-benz[1 ,4]oxazin-6-ol (400 mg, 2.42 mmol) in methanol (2 ml). The reaction mixture is stirred for 30 min at room temperature, neutralized with 25 % aqueous ammonia and the red precipitate is spun down. The crude diazo intermediate is purified by recrystallization (n-butanol); mp: 162-165 °C.
The diazo intermediate (560 mg, 1.78 mmol) and 4-methyl-2-H-benz[1,4]oxazin-6-ol (326 mg, 1.96 mmol) are dissolved in a mixture of ethanol (10 ml) and water (1 ml). After the addition of 32 % HCI (700 μl) the reaction mixture is stirred at 70°C under reflux for 1 h and subsequently the solution is concentrated under reduced pressure. The residue is dissolved in water and treated with a saturated solution of sodium tetrafluoroborate. The precipitate is spun down and purified by column chromatography (SiO2, dichloromethane/methanol = 10/2) to provide the title compound as blue crystals, mp: 235-238 CC. 1H NMR (500 MHz): δ = 3.37 (s, 6 H, 1*-H, T-H), 3.80 (t, 4 H, 3J = 4.8 Hz, 3-H, 9-H), 4.37 (t,
4 H, 3J = 4.8 Hz, 2-H, 10-H), 7.03 (s, 2 H, 5-H, 7-H), 7.21 (s, 2 H, 12-H, 14-H).
Example 4: 4,8-Dimethyl-2.3,9,10-tetrahvdro — H-1.6-dioxa-11-thia-4.13-diaza-8-azonia- pentacen chloride
4-Nitro-benzenediazonium tetrafluoroborate (287 mg, 1.21 mmol) is dissolved in 10 % H2SO4 (200 μl) and is added to a solution of 4-methyl-3,4-dihydro-2H-benzo[1 ,4]thiazin (200 mg, 1.21 mmol) in methanol (2 ml). The reaction mixture is stirred for 30 min at room temperature, neutralized with 25 % aqueous ammonia and the red precipitate is spun down. The crude diazo intermediate is used in the next stage without further purification. The diazo intermediate (150 mg, 477 μmol) and 4-methyl-2-H-benz[1,4]oxazin-6-ol (119 mg, 716 μmol) are dissolved in a mixture of ethanol (4 ml) and water (400 μl). After the addition of 32 % HCI (187 μl) the reaction mixture is heated at 70°C under reflux for 1 h and subsequently the solution is concentrated under reduced pressure. The crude product is purified by column chromatography (SiO2, dichloromethane/methanol = 10/3) to yield: the title compound as blue crystals; mp: 250-252 °C.
1H NMR (500 MHz): δ = 3.17 (t, 2 H, 3J = 4.9 Hz, 10-H), 3.37 (s, 3 H, 1'-H), 3.41 (s, 3 H, X- H), 3.85 (m, 2 H, 9-H), 4.03 (m, 2 H, 3-H), 4.38 (d, 2 H, 3J = 4.3 Hz, 2-H), 6.99 (s, 1 H, 7-H),
7.02 (s, 1 H, 5-H), 7.11 (s, 1 H, 14-H), 7.54 (s, 1 H, 12-H).
Example 5: 8-(3-Ethoxycarbonyl-propyn-4-methyl-3.8.9.10-tetrahvdro-2H-1.6.11-trioxa-8.13- diaza-4-azonia-pentacen chloride
A solution of 3,4-dihydro-2H-1,4-benzoxazin-6-ol (200 mg, 1.32 mmol), potassium carbonate (183 mg, 1.32 mmol) and 4-bromo-butyric acid ethyl ester (217 μl, 1.46 mmol) in anhydrous dimethyl formamide (1 ml) is stirred at 65°C for 16 h under argon. The reaction mixture is poured into water (20 ml), the aqueous phase is neutralized with 2 M HCI and extracted with ethyl acetate (3 x 50 ml). The combined organic phases are dried with MgSO and the solvent is removed under reduced pressure. The crude product is purified by column chromatography (SiO2, hexane/ethyl acetate = 2/1) furnishing a colorless oil; 1H NMR (500 MHz): δ = 1.17 (t, 3 H, 3J = 7.4 Hz, T- ), 1.76 (dd, 2 H, 3J = 7.4 Hz, 2'-H), 2.34 (t, 2 H, 3J =
7.3 Hz, 3'-H), 3.17 (t, 2 H, 3J = 7.4 Hz, 1 '-H), 3.23 (d, 2 H, 3J = 4.5 Hz, 3-H), 4.05 (m, 4 H, 2- H, 6'-H), 5.89 (dd, 1 H, 3J = 7.9 Hz, 4J = 2.4 Hz, 7-H), 6.11 (d, 1 H, 4J = 2.4 Hz, 5-H), 6.42 (d, 1 H, 3 = 7.9 Hz, 8-H), 8.62 (s, 1 H, OH).
The diazo intermediate from Example 3 (150 mg, 565 μmol) and 4-(6-hydroxy-2,3-dihydro- benzo[1 ,4]oxazin-4-yl)-butyric acid ethyl ester (213 mg, 678 μmol) are dissolved in a mixture of ethanol (1 ml) and water (100 μl). After the addition of 32 % HCI (222 μl) the reaction mixture is heated at 70°C under reflux for 1 h and the solution is concentrated under reduced pressure. The residue is purified by column chromatography (SiO2, dichloromethane/ methanol = 10/2) furnishing the title compound as blue crystals, mp: 242-245 °C.
Example 6: UV/VIS and fluorescence properties of compounds of the invention
UV/VIS and fluorescence spectra are recorded and analyzed. For UV/VIS spectra, a Lambda 19 spectrometer from Perkin Elmer equipped with cells of 1.000 cm pathlength is used. The scan rate is 120 nm/min. The fluorescence data are obtained on a Spex Fluorolog (I.S.A.) spectrometer equipped with a cooled R928 detector (Slit 1 mm). Quantum yields are determined by using Cresylviolett (exc. 595 nm, yield = 0.54) as standard.
Table 2: Fluorescent properties of compounds of the invention
Figure imgf000017_0001
Example 7: Labeling of APP23 mouse and human Alzheimer disease (AD) brain sections using a compound of the invention or Thioflavine S
Four-micrometer thick paraffin sections from an APP23 mouse at 26 months of age are deparaffinized in xylene and rehydrated. 10 mg of the agent of the invention (compound Ex.3) is dissolved in 1 ml dimethylsulfoxide and diluted with deionized water 1:10. This staining solution is applied on sections for about 20 min. Section background is cleared by washing with 95% ethanol. Finally, sections are dehydrated in 99% ethanol, cleared in xylene and mounted with Vectashield™. Twenty-micrometer thick cryotome sections from an AD brain cortex are air-dried and fixated in 4% PFA for 5 min. After washing in tap water sections are stained either with Thioflavine S or with the agent of the invention (compound Ex. 3) for 5 min and further processed as described above. The agent of the invention is dissolved in dimethylsulfoxide and diluted to a final concentration of 0.01 % with 50% Ethanol, Thioflavine S is dissolved in 50% Ethanol, final concentration is 0.01 %.
Example 8: In vitro binding properties to amyloid plaques Binding of the agent of the invention (compound Ex.3) to aggregated Aβ peptide Aβ1-40 in solution is investigated by differential fluorescence spectroscopy and thioflavine displacement. The fluorescence spectrum of the agent of the invention (compound Ex.3) shows slightly reduced fluorescence intensity in the range of 680-720 nm upon β-amyioid binding. Difference spectra are recorded at different concentrations of the agent of the invention (compound Ex.3) with the magnitude of the fluorescence shift being dependent on the concentration of aggregated Aβ. Saturation is observed at high concentrations of the agent of the invention (compound Ex.3), and the Kd-value for the agent of the invention (compound Ex.3) is estimated to be 0.2 μM. In another experiment, aggregated Aβ is incubated with thioflavine T, where fluorescence intensity at 460-560 nm (excitation 445 nm) represents thioflavine bound to aggregated Aβ. Addition of the agent of the invention (compound Ex.3) causes a concentration-dependent fluorescence reduction, indicating a displacement of thioflavine from aggregated Aβ, and the apparent binding constant for the agent of the invention (compound Ex.3) can be calculated. The experiment is done at thioflavine concentrations from 0.37 μM - 3 μM, the apparent binding constants for the agent of the invention (compound Ex.3) are between 0.1 μM - 0.2 μM at all thioflavine concentrations and do not increase at higher thioflavine concentrations.
Example 9: In vivo labeling of Aβ in APP23 mice
Injection solution is prepared fresh by dissolving 10 mg of the agent of invention in 0.2 mL dimethylsulfoxide diluted with 9.8 ml sterile water. Lower concentrations are prepared by further dilution with water. Four APP23 female mice at 21 month of age receive one single injection of the compound (Injection volume: 1 ml/100gr body weight). The treated animals are killed by decapitation after one hour. The brains are removed and frozen on dry ice. 14 μm thick sections are cut in a cryotome, thaw mounted and air-dried. Staining is performed as described above. Sections are analyzed using conventional fluorescence microscopy and confocal microscopy.
(i) Staining of APP23 mice brain sections (which contain amyloid deposits but no neurofibrillary tangles): The agents of the invention strongly stain amyloid plaques and vascular amyloid deposits in brain sections of APP23 mice, (ii) Staining of human AD brain sections (which contain both amyloid deposits and neurofibrillary tangles): Brain sections taken from frontal cortex of AD patients are stained with the agents of the invention, and the results compared with a Thioflavine S stain. The agents of the invention intensely and selectively stain amyloid deposits.
(iii) Ex vivo staining in APP23 mice: Intravenous administration of the agents of the invention in APP23 mice leads to a selective and intense staining of amyloid deposits, analyzed ex vivo.
Example 10: Label and real-time detection of beta amyloid plagues and neurofibrillary tangles in vivo using near-infrared imaging
For in vivo near-infrared imaging, 10- to 24-months-old transgenic APP23 mice (3 ≤ n ≤ 5) and as control, non-transgenic APP23 mice of the same age (3 ≤ n ≤ 4) are injected intravenously (i.v.) into the tail-vein with 0.1, 1 and 3 mg/kg agent of invention (0.1 , 1 and 3 mg/10 ml in 0.9% saline). Images are recorded 30, 60, 120 and 240 min after systemic administration. The graph in Fig. 1 shows specific binding of the compound of Example 3 to AD plaques in female 16-months-old transgenic APP23 mice that are injected i.v. with 3 mg/kg agent of invention. Here, specific binding is defined as fluorescence signal(transgenic mice) minus fluorescence signal (non-transgenic mice) divided by fluorescence signal(transgenic mice).
Significant differences in fluorescence signal intensity, i.e. specific binding is observed 60, 120 and 240 min after administration of the agent of invention in transgenic APP23 and non- transgenic control mice thus demonstrating the capability of the agent of invention for labeling amyloid plaques in the brain in order to identify Alzheimer's disease.

Claims

1. Compounds of formula
Figure imgf000020_0001
wherein
X and Y represent CH, CH2 or a divalent or trivalent heteroatom under the proviso that X and Y are not simultaneously CH or CH2; m and o represent independently of each other 0 or 1 , with the proviso that if m is 0 then the dotted line between Y and the neighboring C atom represents a bond and Y is CH or a trivalent heteroatom, if m is 1 then the dotted line between Y and the neighboring C atom is absent and Y is CH2 or a divalent heteroatom, if o is 0 then the dotted line between X and the neighboring C atom represents a bond and X is CH or a trivalent heteroatom, if o is 1 then the dotted line between X and the neighboring C atom is absent and X is CH2 or a divalent heteroatom; A represents (CR3R4)P and Q represents (CR9R10)n; n and p represent independently of each other 0 or 1 ; R6, R7, R13, and R14 denote independently of each other hydrogen, halogen, (C^alkyl, (C-i- 4)alkylSO2, SO3H, carboxy, (d^alkoxy carbonyl, (C^alkoxy, OH or NR15Rιe; Ri, R2, 3, RA, R9, R10, R11 and R12 denote independently of each other hydrogen,
Figure imgf000020_0002
carboxy,
Figure imgf000020_0003
or, when X is CH or CH2 then R1 and R2 can also be OH or NRι5Rι6, or when Y is CH or CH2 then Ru, R12 can also be OH or
R5, Rs, 15 and R16 are independently of each other hydrogen, (C^alkyl, (C^Jalkoxy, R1 O- C(O)-(C1.4)alkyl or (reactive group)-(C1^)alkyl; and R17 represents hydrogen or (C^alkyl; in free base or acid addition salt form.
2. A compound of formula I according to claim 1 in free base or acid addition salt form wherein X is O, S or CH2 and Y is O, S or CH2 with the proviso that X and Y are not both simultaneously CH2.
3. A compound of formula I according to claim 1 wherein said compound is selected from 4,8-dimethyl-2,3,4,9,10,11-hexahydro-1 ,6-dioxa-4,13-diaza-8-azonia-pentacen chloride; 8-ethyl-4-methyl-2,3,4,9, 10,11 -hexahydro-1 ,6-dioxa-4, 13-diaza-8-azonia-pentacen chloride; 4,8-dimethyl-3,8,9,10-tetrahydro-2H-1 ,6,11-trioxa-8,13-diaza-4-azonia-pentacen tetrafluoroborate; 4,8-dimethyl-2,3,9,10-tetrahydro — 4H-1,6-dioxa-11-thia-4,13-diaza-8-azonia-pentacen chloride; and 8-(3-ethoxycarbonyl-propyl)-4-methyl-3,8,9,10-tetrahydro-2H-1 ,6,11-trioxa-8,13-diaza-4- azonia-pentacen chloride.
4. A composition comprising a compound according to of any one of claims 1-3 and a pharmaceutically acceptable excipient or diluent.
5. A process for the production of a compound of formula I or a salt thereof, comprising the steps of reacting a phenol derivative of formula III
Figure imgf000021_0001
wherein the radicals and symbols A, X, Ri, R2, R5, R6, Ru and o have the meanings as defined in claim 1 for a compound of formula I, with a nitroso or diazo compound of formula IV
Figure imgf000022_0001
wherein the radicals and symbols Q, Y, R7, R8, Ru, Rι2, R13 and m have the meanings as defined in claim 1 for a compound of formula I, R18 represents oxo or p-nitrophenyl-N= and R19 represents hydroxy; and recovering the resulting compound of formula I in free base form or in form of an acid addition salt.
6. A method of labeling target structures in the brain comprising:
(i) applying a composition comprising a compound of formula I
Figure imgf000022_0002
wherein
X and Y represent CH, CH2 or a divalent or trivalent heteroatom under the proviso that X and Y are not simultaneously CH or CH2; m and o represent independently of each other 0 or 1 , with the proviso that if m is 0 then the dotted line between Y and the neighboring C atom represents a bond and Y is CH or a trivalent heteroatom, if m is 1 then the dotted line between Y and the neighboring C atom is absent and Y is CH2 or a divalent heteroatom, if o is 0 then the dotted line between X and the neighboring C atom represents a bond and X is CH or a trivalent heteroatom, if o is 1 then the dotted line between X and the neighboring C atom is absent and X is CH2 or a divalent heteroatom; A represents (CR3R )P and Q represents (CR9R10)n; n and p represent independently of each other 0 or 1 ;
Re, R7, i3, and u denote independently of each other hydrogen, halogen, (C1^)alkyl, (Ct- 4)alkylSO2, SO3H, carboxy,
Figure imgf000023_0001
OH or NRι5Rιe; Ri, R2, R3, R , R9, R10, R11 and R12 denote independently of each other hydrogen, (Chalky!, carboxy, (C1-4)alkoxy carbonyl or (C^alkoxy, or, when X is CH or CH2 then Ri and R2 can also be OH or NR15R16, or when Y is CH or CH2 then Ru, Rι2 can also be OH or
Rs, Ra, R15 and Rie are independently of each other hydrogen, (d-^alkyl, (C^Jalkoxy, R17O- C(O)-(Ct^)alkyl or (reactive group)-(Ci )alkyl; and Rι7 represents hydrogen or (C^)alkyl; in free base or acid addition salt form, or of formula ll
Figure imgf000023_0002
wherein
Re, R7, Ri3, and R denote independently of each other hydrogen, halogen, (C^Jalkyl, (d- 4)alkylSO2, SO3H, carboxy, (d^)alkoxy carbonyl, (C1-4)alkoxy, OH or NR 5R16, and R21 and R22 are hydrogen,(Cι^)alkyl, (d^alkoxy, phenyl, phenylalkyl, carboxy or halogen; RM and R22 together with the carbon atoms to which they are attached can also form a saturated or unsaturated ring; R21 and R13 together with the carbon atoms to which they are attached can also form a saturated or unsaturated ring; Rs, Rs, R20 and R23 are hydrogen, (d-^alkyl, (C1-4)alkoxy, polyoxyhydrocarbyl, phenyl, phenylalkyl; R8 and R20 together with the nitrogen atom to which they are attached can form a saturated or unsaturated ring, R23 and R5 together with the nitrogen atom to which they are attached can form a saturated or unsaturated ring, R22 and R23 together with the atoms to which they are attached can form a saturated or unsaturated ring, R5 together with R6 together with the atoms to which they are attached can form a saturated or unsaturated ring, R7 together with R8 together with the atoms to which they are attached can form a saturated or unsaturated ring, R20 together with R2 together with the atoms to which they are attached can form a saturated or unsaturated ring,
(ii) allowing sufficient time for said compound to be chemically associated with the target structure in the brain, and (iii) detecting said compound using near-infrared radiation.
7. The method according to claim 6 wherein said target structures are amyloid plaques.
8. The method according to claim 7 for identifying diseases related to amyloid plaque generation and/or aggregation.
9. The method according to claim 7 or claim 8 for identifying Alzheimer's disease.
10. Use of a compound of formula I according to any one of claims 1-3 in free base or acid addition salt form as a near-infrared imaging agent.
11. Use of a compound of formula II as defined in claim 6 as a near-infrared imaging agent.
12. Use according to claims 10 or 11 as a near-infrared imaging agent to image amyloid plaques.
13. A conjugate comprising a compound of formula I according to any one of claims 1-3 covalently linked to a biomolecule through a reactive group.
14. A conjugate according to claim 13 wherein the biomolecule is selected from the group consisting of nucleoside, nucleotide, oligonucleotide, nucleic acid, protein, peptide, amino acid, polysaccharide, oligosaccharide, monosaccharide, drug or a small molecule having a molecular weight of less than 500.
15. A conjugate according to claim 13 or 14 capable of being detected using near-infrared radiation.
PCT/EP2004/009225 2003-08-18 2004-08-17 3h-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof Ceased WO2005016934A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP04764213A EP1658294B1 (en) 2003-08-18 2004-08-17 3h-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof
CA002535873A CA2535873A1 (en) 2003-08-18 2004-08-17 3h-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof
BRPI0413703-5A BRPI0413703A (en) 2003-08-18 2004-08-17 3h-phenoxazine derivatives suitable as near infrared imaging agents, preparation and use thereof
MXPA06001891A MXPA06001891A (en) 2003-08-18 2004-08-17 3h-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof.
US10/568,841 US20070031336A1 (en) 2003-08-18 2004-08-17 3H-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof
JP2006523596A JP2007502798A (en) 2003-08-18 2004-08-17 3H-phenoxazine derivative suitable for near-infrared contrast agent, its production method and use
AU2004264387A AU2004264387B2 (en) 2003-08-18 2004-08-17 3H-phenoxazine derivatives suitable as near-infrared imaging agents, preparation and use thereof
DE602004004280T DE602004004280T2 (en) 2003-08-18 2004-08-17 3H-PHENOXAZINE DERIVATIVES SUITABLE FOR NEAR-FROSTED REPRODUCTION, THEIR PREPARATION AND USE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49592103P 2003-08-18 2003-08-18
US60/495,921 2003-08-18

Publications (1)

Publication Number Publication Date
WO2005016934A1 true WO2005016934A1 (en) 2005-02-24

Family

ID=34193359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/009225 Ceased WO2005016934A1 (en) 2003-08-18 2004-08-17 3h-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof

Country Status (11)

Country Link
US (1) US20070031336A1 (en)
EP (1) EP1658294B1 (en)
JP (1) JP2007502798A (en)
CN (1) CN100447145C (en)
AU (1) AU2004264387B2 (en)
BR (1) BRPI0413703A (en)
CA (1) CA2535873A1 (en)
DE (1) DE602004004280T2 (en)
ES (1) ES2279422T3 (en)
MX (1) MXPA06001891A (en)
WO (1) WO2005016934A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014032732A1 (en) 2012-08-28 2014-03-06 Eberhard Karls Universität Tübingen Medizinische Fakultät Halogenated benzoxazines and use thereof
CN115279423A (en) * 2020-01-24 2022-11-01 俄勒冈健康与科学大学 Oxazine-based fluorophore compounds for neurospecific imaging

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735575B2 (en) 2010-07-30 2014-05-27 Washington University Phenoxazine derivatives and methods of use thereof
US9977016B2 (en) * 2015-11-05 2018-05-22 Kansas State University Research Foundation Two-dimensional fluorescence difference spectroscopy characterization of nanoparticles and their interactions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1193260A1 (en) * 2000-09-29 2002-04-03 Warner-Lambert Company Phenoxazine analogs for the treatment of amyloidosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
DE19521231A1 (en) * 1995-06-10 1996-12-12 Boehringer Mannheim Gmbh New oxazine dyes and their use as fluorescent markers
DE19649971A1 (en) * 1996-11-19 1998-05-28 Diagnostikforschung Inst Optical diagnostics for the diagnosis of neurodegenerative diseases using near-infrared radiation (NIR radiation)
JP2000344684A (en) * 1999-03-26 2000-12-12 Bf Kenkyusho:Kk Graphic diagnosis probe for disease accepting accumulating amyloid by pyronine b analog compound and composition for graphic diagnosis containing the same
EP1088559A3 (en) * 1999-09-29 2002-10-02 INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN Galenic formulations
ATE287430T1 (en) * 2000-09-06 2005-02-15 Evotec Ag OXAZINE DERIVATIVES
DE50106822D1 (en) * 2000-11-16 2005-08-25 Roche Diagnostics Gmbh DYES FOR FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) MEASUREMENTS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1193260A1 (en) * 2000-09-29 2002-04-03 Warner-Lambert Company Phenoxazine analogs for the treatment of amyloidosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H. MICHAEL PETRASSI ET AL..: "Structure-based Design of N-Phenyl Phenoxazine Transthyretin Amyloid Fibril Inhibitors", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 122, no. 10, 15 March 2000 (2000-03-15), COLUMBUS OHIO, pages 2178 - 2179, XP002306598 *
WISCHIK C M ET AL: "SELECTIVE INHIBITION OF ALZHEIMER DISEASE-LIKE TAU AGGREGATION BY PHENOTHIAZINES", October 1996, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, PAGE(S) 11213-11218, ISSN: 0027-8424, XP002067057 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014032732A1 (en) 2012-08-28 2014-03-06 Eberhard Karls Universität Tübingen Medizinische Fakultät Halogenated benzoxazines and use thereof
US20150166572A1 (en) * 2012-08-28 2015-06-18 Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet Halogenated benzoxazines and their use
US9796730B2 (en) 2012-08-28 2017-10-24 Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet Halogenated benzoxazines and their use
CN115279423A (en) * 2020-01-24 2022-11-01 俄勒冈健康与科学大学 Oxazine-based fluorophore compounds for neurospecific imaging
US20230148317A1 (en) * 2020-01-24 2023-05-11 Oregon Health & Science University Oxazine-based fluorophore compounds for nerve-specific imaging
EP4093443A4 (en) * 2020-01-24 2024-08-21 Oregon Health & Science University OXAZINE-BASED FLUOROPHOREUS COMPOUNDS FOR NERVE-SPECIFIC IMAGING

Also Published As

Publication number Publication date
DE602004004280T2 (en) 2007-06-21
US20070031336A1 (en) 2007-02-08
CN100447145C (en) 2008-12-31
CN1835955A (en) 2006-09-20
MXPA06001891A (en) 2006-05-17
EP1658294A1 (en) 2006-05-24
BRPI0413703A (en) 2006-10-17
JP2007502798A (en) 2007-02-15
CA2535873A1 (en) 2005-02-24
ES2279422T3 (en) 2007-08-16
AU2004264387B2 (en) 2008-06-12
AU2004264387A1 (en) 2005-02-24
DE602004004280D1 (en) 2007-02-22
EP1658294B1 (en) 2007-01-10

Similar Documents

Publication Publication Date Title
US7569337B2 (en) Coumarines useful as biomarkers
JPWO2010126077A1 (en) Near-infrared fluorescent compound
US20200022955A1 (en) SPECIFICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY
CN111196819B (en) D-A-D type benzopyrazines compound, preparation method and application thereof
CN110143974B (en) A new class of artemisinin derivatives, synthetic method and use thereof
CN109879884B (en) Fluorescent probe for detecting viscosity, preparation method and application thereof
EP1658294B1 (en) 3h-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof
CN117186151B (en) A near-infrared zwitterionic cyanine dye and its preparation method and application
US20090068113A1 (en) Amphiphilic squaraine dyes, process for preparation thereof and use thereof
US20080275232A1 (en) Chlorins possessing fused ring systems useful as photoselective compounds for photodynamic therapy
KR101578384B1 (en) A composition for simultaneous imaging of lysosomes and mitochondria in live cell and tissue, and method of imaging the lysosomes and mitochondria in live cell using the same
US9795694B2 (en) Imaging beta-amyloid peptides aggregation
US20210252170A1 (en) Targeted contrast agents for mri of alpha-synuclein deposition
AU2005275220B2 (en) Adduct of fluorescent dye and tumor avid tetrapyrrole
CN113683562A (en) A novel near-infrared second-region dye resistant to solvent quenching, preparation method and application thereof
KR20220122978A (en) Tricyclic compounds and methods for their preparation and medical uses thereof
You et al. Rational design of a high-affinity fluorescent probe for visualizing monitoring the amyloid β clearance effect of anti-Alzheimer's disease drug candidates
US11779664B2 (en) Targeted contrast agents for MRI of alpha-synuclein deposition
JP2025516331A (en) Preparation and Uses of 7-Azaindenoisoquinolines
KR20080033286A (en) Cripowellin and its synthetic derivatives for use as a medicament
CN117088858A (en) Application of an orthogonal charge transfer cationic organic small molecule in phototherapy
Lee Syntheses of porphyrins and synthetic modification of chlorophylls
AU2007203498A1 (en) Coumarines useful as biomarkers
HK1243722A1 (en) Selective cancer tracking eradicator and the uses thereof
HK1243722B (en) Selective cancer tracking eradicator and the uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480023528.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004264387

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2535873

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 569/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004764213

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/001891

Country of ref document: MX

Ref document number: 2006523596

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004264387

Country of ref document: AU

Date of ref document: 20040817

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004264387

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004764213

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007031336

Country of ref document: US

Ref document number: 10568841

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0413703

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2004764213

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10568841

Country of ref document: US